Evidence map›Paper›PMID 36498739›Full record

ArticleJournal of clinical medicine2022

Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple Sclerosis.

Sara Siddi, Iago Giné-Vázquez, Raquel Bailon, Faith Matcham, Femke Lamers, Spyridon Kontaxis, Estela Laporta, Esther Garcia, Belen Arranz, Gloria Dalla Costa and 37 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors at 17 institutions in 8 countries.

Sara SiddiParc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM (Madrid 28029), Universitat de Barcelona, 08007 Barcelona, Spain.ORCID 0000-0002-1494-9028
Iago Giné-VázquezParc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM (Madrid 28029), Universitat de Barcelona, 08007 Barcelona, Spain.ORCID 0000-0002-6725-2638
Raquel BailonAragón Institute of Engineering Research (I3A), University of Zaragoza, 50001 Zaragoza, Spain.ORCID 0000-0003-1272-0550
Faith MatchamInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Femke LamersDepartment of Psychiatry, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0003-4344-5766
Spyridon KontaxisAragón Institute of Engineering Research (I3A), University of Zaragoza, 50001 Zaragoza, Spain.
Estela LaportaCentros de Investigación Biomédica en Red en el Área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain.ORCID 0000-0001-6776-8522
Esther GarciaCentros de Investigación Biomédica en Red en el Área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain.
Belen ArranzParc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM (Madrid 28029), Universitat de Barcelona, 08007 Barcelona, Spain.
Gloria Dalla CostaFaculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Ana Isabel GuerreroMultiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0001-5891-2123
Ana ZabalzaMultiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0003-3860-5251
Mathias Due BuronDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark.ORCID 0000-0003-1260-1156
Giancarlo ComiFaculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Letizia LeocaniFaculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Peter AnnasH. Lundbeck A/S, 2500 Valby, Denmark.
Matthew HotopfInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Brenda W J H PenninxDepartment of Psychiatry, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
Melinda MagyariDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark.
Per S SørensenDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark.ORCID 0000-0002-2818-3780
Xavier MontalbanMultiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0002-0098-9918
Grace LavelleInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Alina IvanInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Carolin OetzmannInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.ORCID 0000-0003-1480-917X
Katie M WhiteInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Sonia DifrancescoDepartment of Psychiatry, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0001-7254-3686
Patrick LocatelliDepartment of Engineering and Applied Science, University of Bergamo, 24129 Bergamo, Italy.ORCID 0000-0002-3796-8512
David C MohrCenter for Behavioral Intervention Technologies, Department of Preventative Medicine, Northwestern University, Chicago, IL 60611, USA.
Jordi AguilóCentros de Investigación Biomédica en Red en el Área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain.
Vaibhav NarayanResearch and Development Information Technology, Janssen Research & Development, LLC, Titusville, NJ 08560, USA.
Amos FolarinInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.ORCID 0000-0002-0333-1927
Richard J B DobsonInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Judith DineleyInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Daniel LeightleyInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.ORCID 0000-0001-9512-752X
Nicholas CumminsInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Srinivasan VairavanResearch and Development Information Technology, Janssen Research & Development, LLC, Titusville, NJ 08560, USA.
Yathart RanjanInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Zulqarnain RashidInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Aki RintalaDepartment for Neurosciences, Center for Contextual Psychiatry, Katholieke Universiteit Leuven, 7001 Leuven, Belgium.ORCID 0000-0002-0066-4697
Giovanni De GirolamoIRCCS Instituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
Antonio PretiDipartimento di Neuroscienze, Università degli Studi di Torino, 10126 Torino, Italy.ORCID 0000-0001-9003-9838
Sara SimblettInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.
Til WykesInstitute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.ORCID 0000-0002-5881-8003
Pab Members
Inez Myin-GermeysDepartment for Neurosciences, Center for Contextual Psychiatry, Katholieke Universiteit Leuven, 7001 Leuven, Belgium.ORCID 0000-0002-3731-4930
Josep Maria HaroParc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM (Madrid 28029), Universitat de Barcelona, 08007 Barcelona, Spain.
On Behalf Of The Radar-Cns Consortium
King's College London · GBParc Sanitari Sant Joan de Déu · ESUniversitat Autònoma de Barcelona · ESAmsterdam University Medical Centers · NLCopenhagen University Hospital · DKVita-Salute San Raffaele University · ITJanssen (United States) · USUniversidad de Zaragoza · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESCentro San Giovanni di Dio Fatebenefratelli · ITKU Leuven · BELAB University of Applied Sciences · FILundbeck (Denmark) · DKNorthwestern University · USUniversity of Bergamo · ITUniversity of Sussex · GBUniversity of Turin · IT

Funding

Medical Research Council MC_PC_17214Medical Research Council MR/K015516/1the Innovative Medicines Initiative 2 Joint Undertaking 115902
6 · The paper itself

Abstract

backgroundChanges in lifestyle, finances and work status during COVID-19 lockdowns may have led to biopsychosocial changes in people with pre-existing vulnerabilities such as Major Depressive Disorders (MDDs) and Multiple Sclerosis (MS).

methodsData were collected as a part of the RADAR-CNS (Remote Assessment of Disease and Relapse-Central Nervous System) program. We analyzed the following data from long-term participants in a decentralized multinational study: symptoms of depression, heart rate (HR) during the day and night; social activity; sedentary state, steps and physical activity of varying intensity. Linear mixed-effects regression analyses with repeated measures were fitted to assess the changes among three time periods (pre, during and post-lockdown) across the groups, adjusting for depression severity before the pandemic and gender.

resultsParticipants with MDDs (N = 255) and MS (N = 214) were included in the analyses. Overall, depressive symptoms remained stable across the three periods in both groups. A lower mean HR and HR variation were observed between pre and during lockdown during the day for MDDs and during the night for MS. HR variation during rest periods also decreased between pre- and post-lockdown in both clinical conditions. We observed a reduction in physical activity for MDDs and MS upon the introduction of lockdowns. The group with MDDs exhibited a net increase in social interaction via social network apps over the three periods.

conclusionsBehavioral responses to the lockdown measured by social activity, physical activity and HR may reflect changes in stress in people with MDDs and MS. Remote technology monitoring might promptly activate an early warning of physical and social alterations in these stressful situations. Future studies must explore how stress does or does not impact depression severity.

Indexed as

COVID-19decentralizeddepression severityheart ratemajor depressive disordermultiple sclerosisphysical activitySARS-CoV-2social activitystress

Identifiers

PMID36498739
PMCPMC9738639
OpenAlexW4311162267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.